BVA for Cardiorenal Syndrome

About Daxor

Daxor Corporation's mission is to advance healthcare by enabling optimal fluid management through its proprietary Blood Volume Analysis (BVA) technology. The company has achieved FDA clearance for its next-generation Daxor BVA Analyzer, built on a foundation of over 75,000 tests and 175+ peer-reviewed studies demonstrating improved outcomes in heart failure and ICU settings. Its strategy centers on commercializing this rapid, portable system to address the 'silent crisis' of volume mismanagement in value-based care, leveraging its U.S. manufacturing facility for scale.

Therapeutic Areas